VanEck Associates’s PRA Health Sciences, Inc. PRAH Stock Holding History

VanEck Associates’s Portfolio PRAH Stock Details PRAH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-664	Closed	-$73K	–	862
2019 Q1	$73K	Hold	664	–	–	﹤0.01%	769
2018 Q4	$61K	Buy	664 +13	+2%	+$1.31K	﹤0.01%	752
2018 Q3	$72K	Sell	651 -24	-4%	-$2.5K	﹤0.01%	743
2018 Q2	$63K	Hold	675	–	–	﹤0.01%	763
2018 Q1	$56K	Buy	675 +28	+4%	+$2.49K	﹤0.01%	644
2017 Q4	$59K	Sell	647 -9	-1%	-$749	﹤0.01%	637
2017 Q3	$50K	Sell	656 -5	-0.8%	-$378	﹤0.01%	714
2017 Q2	$50K	Sell	661 -223	-25%	-$15.5K	﹤0.01%	722
2017 Q1	$58K	Buy	884 +147	+20%	+$8.66K	﹤0.01%	819
2016 Q4	$41K	Buy	737 +364	+98%	+$20K	﹤0.01%	784
2016 Q3	$21K	Buy	373 +177	+90%	+$8.68K	﹤0.01%	843
2016 Q2	$8K	Buy	196 +18	+10%	+$829	﹤0.01%	852
2016 Q1	$8K	Buy	+178	New	+$7.52K	﹤0.01%	813

Other funds holding PRAH

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

VanEck Associates's PRAH Position: Q2 2019 in Review

VanEck Associates sold out of PRA Health Sciences, Inc. (PRAH) in Q2 2019, closing a stake of 664 shares — an estimated $73K sold.

VanEck Associates first reported a position in PRAH in Q1 2016 and held it in 13 quarters. The position peaked at $73K in Q1 2019. 329 funds tracked by Wall St. Rank hold PRAH as of Q2 2019.

VanEck Associates reported no remaining PRA Health Sciences, Inc. position as of Q2 2019 after selling out during the quarter.
VanEck Associates sold 664 PRA Health Sciences, Inc. shares in Q2 2019, an estimated $73K.
VanEck Associates first reported a position in PRA Health Sciences, Inc. in Q1 2016 and held it in 13 quarters.
VanEck Associates's PRA Health Sciences, Inc. position peaked at $73K in Q1 2019.
329 funds tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q2 2019.

Based on VanEck Associates's 13F filing for Q2 2019, filed 7 Aug 2019.